Exhibit 25.3
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM T-1
STATEMENT OF ELIGIBILITY
UNDER THE TRUST INDENTURE ACT OF 1939 OF A
CORPORATION DESIGNATED TO ACT AS TRUSTEE
UNDER THE TRUST INDENTURE ACT OF 1939 OF A
CORPORATION DESIGNATED TO ACT AS TRUSTEE
CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY
OF A TRUSTEE PURSUANT TO SECTION 305(b)(2)
OF A TRUSTEE PURSUANT TO SECTION 305(b)(2)
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
(Exact name of trustee as specified in its charter)
Delaware | 95-3571558 | |
(State of incorporation if not a U.S. national bank) | (I.R.S. employer identification no.) | |
700 South Flower Street, Suite 500 | ||
Los Angeles, California | 90017 | |
(Address of principal executive offices) | (Zip code) |
INVERNESS MEDICAL INNOVATIONS, INC.
(Exact name of obligor as specified in its charter)
(See table of additional obligors on following page)
(Exact name of obligor as specified in its charter)
(See table of additional obligors on following page)
Delaware (State of incorporation if not a U.S. national bank) | 04-3565120 (I.R.S. employer identification no.) | |
51 Sawyer Road, Suite 200 | 02453 | |
Waltham, Massachusetts | (Zip code) | |
(Address of principal executive offices) |
Senior Notes Due 2016
(Title of the indenture securities)
TABLE OF ADDITIONAL OBLIGORS
Some or all of the following direct and indirect wholly owned domestic subsidiaries of Inverness Medical Innovations, Inc. are expected to guarantee the debt securities issued pursuant to the Indenture. The address, including zip code, and telephone number, including area code, of each of the co-obligors is 51 Sawyer Road, Suite 200, Waltham, Massachusetts, 02453, (781) 647-3900:
State or other | ||||||
jurisdiction of | ||||||
Exact name of additional registrant | incorporation or | I.R.S. Employer | ||||
as specified in its charter | organization | Identification Number | ||||
Advantage Diagnostics Corporation | Delaware | 20-1247157 | ||||
Alere LLC | Delaware | 26-2564744 | ||||
Alere CDM LLC | Delaware | 27-0653943 | ||||
Alere Healthcare of Illinois, Inc. | Georgia | 58-2068880 | ||||
Alere Health Improvement Company | Delaware | 23-2776413 | ||||
Alere Health Systems, Inc. | Delaware | 22-3493126 | ||||
Alere Medical, Inc. | California | 94-3238845 | ||||
Alere Wellology, Inc. | Delaware | 54-1776557 | ||||
Alere Women’s and Children’s Health, LLC | Delaware | 58-2205984 | ||||
Ameditech Inc. | California | 33-0859551 | ||||
Applied Biotech, Inc. | California | 33-0447325 | ||||
Binax, Inc. | Delaware | 20-2507302 | ||||
Biosite Incorporated | Delaware | 33-0288606 | ||||
Cholestech Corporation | Delaware | 94-3065493 | ||||
First Check Diagnostics Corp. | Delaware | 20-8329751 | ||||
First Check Ecom, Inc. | Massachusetts | 33-1026518 | ||||
Genecare Medical Genetics Center, Inc. | North Carolina | 56-1348485 | ||||
Hemosense, Inc. | Delaware | 77-0452938 | ||||
IM US Holdings, LLC | Delaware | 26-0349667 | ||||
Innovacon, Inc. | Delaware | 20-1100264 | ||||
Innovations Research, LLC | Delaware | 20-0653511 | ||||
Innovative Mobility, LLC | Florida | 20-0351538 | ||||
Instant Technologies, Inc. | Virginia | 54-1837621 | ||||
Inverness Medical, LLC | Delaware | 26-0392649 | ||||
Inverness Medical — Biostar Inc. | Delaware | 91-1929582 | ||||
Inverness Medical Innovations North America, | Delaware | 26-1444559 | ||||
Inc. Inverness Medical International Holding Corp. | Delaware | 80-0077873 | ||||
Inverness Medical International Holding Corp. II | Delaware | 20-0963463 | ||||
Ischemia Technologies, Inc. | Delaware | 84-1489537 | ||||
IVC Industries, Inc. | Delaware | 22-1567481 | ||||
Matria of New York, Inc. | New York | 58-1873062 | ||||
Matritech, Inc. | Delaware | 26-1436477 | ||||
Ostex International, Inc. | Washington | 91-1450247 | ||||
Quality Assured Services, Inc. | Florida | 59-3437644 | ||||
Redwood Toxicology Laboratory, Inc. | California | 68-0332937 | ||||
RTL Holdings, Inc. | Delaware | 20-4371685 | ||||
Selfcare Technology, Inc. | Delaware | 04-3383533 | ||||
Wampole Laboratories, LLC | Delaware | 37-1485678 |
- 2 -
1. | General information. Furnish the following information as to the trustee: |
(a) | Name and address of each examining or supervising authority to which it is subject. |
Name | Address | |
Comptroller of the Currency – United States Department of the Treasury | Washington, D.C. 20219 | |
Federal Reserve Bank | San Francisco, California 94105 | |
Federal Deposit Insurance Corporation | Washington, D.C. 20429 |
(b) | Whether it is authorized to exercise corporate trust powers. | ||
Yes. |
2. | Affiliations with Obligor. | |
If the obligor is an affiliate of the trustee, describe each such affiliation. | ||
None. |
16. | List of Exhibits. | |
Exhibits identified in parentheses below, on file with the Commission, are incorporated herein by reference as an exhibit hereto, pursuant to Rule 7a-29 under the Trust Indenture Act of 1939 (the “Act”) and 17 C.F.R. 229.10(d). |
1. | A copy of the articles of association of The Bank of New York Mellon Trust Company, N.A. (Exhibit 1 to Form T-1 filed with Registration Statement No. 333-121948 which is incorporated by reference). | ||
2. | A copy of certificate of authority of the trustee to commence business. (Exhibit 2 to Form T-1 filed with Registration Statement No. 333-121948 which is incorporated by reference). | ||
3. | A copy of the authorization of the trustee to exercise corporate trust powers. (Exhibit 3 to Form T-1 filed with Registration Statement No. 333-121948 which is incorporated by reference). | ||
4. | A copy of the existing by-laws of the trustee. (Exhibit 4 to Form T-1 filed with Registration Statement No. 333-121948 which is incorporated by reference). | ||
5. | Not applicable. | ||
6. | The consent of the trustee required by Section 321(b) of the Act. (Exhibit 6 to Form T-1 filed with Registration Statement No. 333-121948 which is incorporated by reference). |
- 3 -
7. | A copy of the latest report of condition of the Trustee published pursuant to law or to the requirements of its supervising or examining authority. | ||
8. | Not applicable. | ||
9. | Not applicable. |
- 4 -
SIGNATURE
Pursuant to the requirements of the Act, the trustee, The Bank of New York Mellon Trust Company, N.A., a banking association organized and existing under the laws of the United States of America, has duly caused this statement of eligibility to be signed on its behalf by the undersigned, thereunto duly authorized, all in The City of Boston, and State of Massachusetts, on the 4th day of August, 2009.
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. | ||||
By: | /s/ Peter M. Murphy | |||
Name: | Peter M. Murphy | |||
Title: | Vice President |
- 5 -
EXHIBIT 7
Consolidated Report of Condition of
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
of 700 South Flower Street, Suite 200, Los Angeles, CA 90017
THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
of 700 South Flower Street, Suite 200, Los Angeles, CA 90017
At the close of business December 31, 2008, published in accordance with Federal regulatory authority instructions.
Dollar Amounts | ||||
in Thousands | ||||
ASSETS | ||||
Cash and balances due from depository institutions: | ||||
Noninterest-bearing balances and currency and coin | 2,739 | |||
Interest-bearing balances | 0 | |||
Securities: | ||||
Held-to-maturity securities | 26 | |||
Available-for-sale securities | 430,112 | |||
Federal funds sold and securities purchased under agreements to resell: | ||||
Federal funds sold | 28,500 | |||
Securities purchased under agreements to resell | 50,000 | |||
Loans and lease financing receivables: | ||||
Loans and leases held for sale | 0 | |||
Loans and leases, net of unearned income | 0 | |||
LESS: Allowance for loan and lease losses | 0 | |||
Loans and leases, net of unearned income and allowance | 0 | |||
Trading assets | 0 | |||
Premises and fixed assets (including capitalized leases) | 11,261 | |||
Other real estate owned | 0 | |||
Investments in unconsolidated subsidiaries and associated companies | 1 | |||
Not applicable | ||||
Intangible assets: | ||||
Goodwill | 876,153 | |||
Other intangible assets | 272,502 | |||
Other assets | 181,657 | |||
Total assets | $ | 1,852,951 | ||
- 6 -
Dollar Amounts | ||||
in Thousands | ||||
LIABILITIES | ||||
Deposits: | ||||
In domestic offices | 1,765 | |||
Noninterest-bearing | 1,765 | |||
Interest-bearing | 0 | |||
Not applicable | ||||
Federal funds purchased and securities sold under agreements to repurchase: | ||||
Federal funds purchased | 0 | |||
Securities sold under agreements to repurchase | 0 | |||
Trading liabilities | 0 | |||
Other borrowed money: | ||||
(includes mortgage indebtedness and obligations under capitalized leases) | 268,691 | |||
Not applicable | ||||
Not applicable | ||||
Subordinated notes and debentures | 0 | |||
Other liabilities | 166,958 | |||
Total liabilities | 437,414 | |||
Minority interest in consolidated subsidiaries | 0 | |||
EQUITY CAPITAL | ||||
Perpetual preferred stock and related surplus | 0 | |||
Common stock | 1,000 | |||
Surplus (exclude all surplus related to preferred stock) | 1,121,520 | |||
Retained earnings | 290,517 | |||
Accumulated other comprehensive income | 2,500 | |||
Other equity capital components | 0 | |||
Total equity capital | 1,415,537 | |||
Total liabilities, minority interest, and equity capital | 1,852,951 | |||
I, Karen Bayz, Vice President of the above-named bank do hereby declare that the Reports of Condition and Income (including the supporting schedules) for this report date have been prepared in conformance with the instructions issued by the appropriate Federal regulatory authority and are true to the best of my knowledge and belief.
Karen Bayz ) Vice President
We, the undersigned directors (trustees), attest to the correctness of the Report of Condition (including the supporting schedules) for this report date and declare that it has been examined by us and to the best of our knowledge and belief has been prepared in conformance with the instructions issued by the appropriate Federal regulatory authority and is true and correct.
Troy Kilpatrick, President | ) | |||||
Frank P. Sulzberger, MD | ) | Directors (Trustees) | ||||
William D. Lindelof, VP | ) |
- 7 -